DNT and EMD Biosciences sign siRNA and DNA reagent license and supply agreement
Under the terms of this agreement, DNT will supply EMD Biosciences with PrioFect(TM) transfection reagents based on Priostar(TM) proprietary dendrimers for the DNA and siRNA transfection research markets. Terms of the agreement which includes royalties and milestone payments were not disclosed.
DNT's PrioFect transfection reagents are part of the market for nucleic acid, DNA and small interfering RNA (siRNA) research. According to the company, PrioFect transfection reagents are the only transfection reagents with nanometer-size control.
Under this commercial arrangement DNT retains full rights to all in vivo aspects of transfecting nucleic acids with Priostar technology.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.